IMVT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Immunovant Inc (IMVT) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 to invest. While the technical indicators show a bullish trend and hedge funds are increasing their positions, the company's financial performance is weak, with declining net income and EPS. Additionally, there are no significant news catalysts or recent congress trading data to support a buy decision. The options data suggests a strong call bias, but this is more indicative of short-term sentiment rather than long-term potential.
The technical indicators are bullish. The MACD is positively expanding, RSI is neutral at 66.362, and the moving averages show a bullish alignment (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 26.997, with resistance at 28.586 and support at 25.408. However, the price trend is relatively flat, with minor gains expected in the short term (0.54% in the next day, 1.48% in the next week, 2.58% in the next month).
Hedge funds are significantly increasing their positions, with a 133.13% increase in buying activity over the last quarter. Analysts from Guggenheim and Wolfe Research have provided positive ratings, with a price target as high as $44.
The company's financial performance is weak, with declining net income (-0.44% YoY) and EPS (-19.74% YoY). There are no significant news catalysts or recent congress trading data. Insider trading is neutral, showing no strong insider confidence.
In Q3 2026, the company reported zero revenue growth, a net income decline of -0.44% YoY to -$110.635 million, and a significant drop in EPS by -19.74% YoY to -0.61. Gross margin remains at 0, indicating no profitability.
Analysts are mixed. Guggenheim has a Buy rating with a price target of $44, while Truist maintains a Hold rating with a price target of $23. Wolfe Research upgraded the stock to Outperform recently, showing some positive sentiment.
